Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma

Fig. 1

Sorafenib inhibits IFNα production by PBMCs in patients with HCC. PBMCs obtained from patients with advanced HCC were stimulated with CpG-A for 24 h. Seven patients received two tablets of sorafenib (200 mg tablet) twice daily for at least 3 months; 11 patients with advanced HCC were included as control. IFNα production was measured by ELISA. Each dot represents an individual donor, and the bars represent the mean ± S.D. **p < 0.01

Back to article page